Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro — and generics of Novo's diabetes drug,

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.

Key Takeaways Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.The treatments will each cost $1,